Cxbladder is a family of urine-based genomic tests used to estimate the likelihood of urothelial carcinoma, the most common type of bladder cancer. Rather than measuring one protein, Cxbladder analyzes gene signals in a midstream urine sample and combines them in a mathematical algorithm. Current versions include Cxbladder Triage for hematuria risk assessment, Cxbladder Triage Plus, which adds selected DNA variants to the established messenger RNA panel, and Cxbladder Monitor for people being followed after urothelial cancer. The meaning of a “low,” “intermediate,” or “high” score therefore depends on which assay was ordered. A low-risk result can reduce the probability of urothelial cancer in an appropriately selected patient, but no urine marker should be interpreted without the person’s hematuria history, smoking exposure, age, prior bladder cancer, imaging, and cystoscopy plan. A positive or higher-risk Cxbladder result is a reason for further evaluation, not a cancer diagnosis.
- What it analyzes: Core Cxbladder assays measure five urinary mRNA markers—MDK, HOXA13, CDK1 (CDC2), IGFBP5, and CXCR2.
- Triage Plus: The newer assay also evaluates selected FGFR3 and TERT DNA variants to improve hematuria risk stratification.
- Result meaning depends on version: Triage/Triage Plus estimate cancer probability in hematuria evaluation; Monitor estimates the likelihood of recurrent urothelial cancer.
- A low score is mainly a rule-out signal: High negative predictive value is useful for identifying selected patients with a low probability of urothelial carcinoma.
- A high score does not prove cancer: Cystoscopy, imaging, and tissue diagnosis remain necessary when the clinical situation warrants them.
Table of Contents
- How Cxbladder Works and Which Genes It Measures
- Cxbladder Triage, Triage Plus, Detect, and Monitor
- Who May Be Tested and Why
- Urine Sample Collection and Processing
- Understanding Cxbladder Risk Scores
- Accuracy, Limitations, and Comparison With Other Tests
- What Happens After the Result
How Cxbladder Works and Which Genes It Measures
Cxbladder is different from older single-protein urine tumor markers. It analyzes molecular material shed into urine from cells lining the urinary tract. The core assay measures the expression of five messenger RNA (mRNA) targets. Messenger RNA reflects which genes are active in a cell at the time the sample is collected.
The five established Cxbladder mRNA markers are:
- MDK (midkine): involved in cell growth, migration, and blood-vessel formation;
- HOXA13: involved in development and differentiation of the genitourinary tract;
- CDK1, historically called CDC2: a cell-cycle gene linked with cell division;
- IGFBP5: involved in growth-factor signaling and cell survival;
- CXCR2: related to inflammatory signaling and used in the model partly to account for non-cancer inflammation.
The laboratory extracts RNA from a small urine sample and measures these targets with reverse-transcription quantitative polymerase chain reaction. The relative expression values are entered into a validated algorithm rather than interpreted one gene at a time.
Cxbladder Triage Plus expands this concept. In addition to the five mRNA markers, it analyzes six selected DNA single-nucleotide variants from FGFR3 and TERT, two genes commonly altered in urothelial tumors. The combination is intended to improve separation of low-probability patients from those who should proceed promptly to further evaluation.
This multigene design does not mean the test sequences the entire tumor genome. It measures a defined set of urinary biomarkers chosen for a specific clinical classification task. A different test such as UroVysion FISH examines chromosomal changes in urine cells, while Cxbladder uses RNA expression and, in Triage Plus, selected DNA variants.
Cxbladder Triage, Triage Plus, Detect, and Monitor
The word “Cxbladder” is sometimes used as though it were one test, but the product family has several assays with different intended uses and score systems. This is the most important fact to check before interpreting a report.
Cxbladder Triage was developed to help identify hematuria patients who have a low probability of urothelial carcinoma. The established Triage algorithm combines the five mRNA biomarkers with clinical risk factors such as age, sex, smoking history, and hematuria characteristics. Its historical score range is 0 to 10, with a cutoff of 4 used to identify a low-probability group.
Cxbladder Triage Plus is a newer version that combines the five mRNA targets with FGFR3 and TERT DNA variants. Current reports use a 0.0 to 1.0 score. Manufacturer interpretation divides results into low, intermediate, and high probability categories. Because this assay is newer, readers should make sure that published performance data and cutoffs refer specifically to Triage Plus rather than to the earlier Triage assay.
Cxbladder Detect is an earlier detection-focused assay based primarily on the mRNA panel. Published analytical validation described a 0.00 to 1.00 score with low-, intermediate-, and high-gene-expression categories. In 2026, clinical use and availability may differ by region as the Cxbladder suite evolves, so the current laboratory report should be treated as the definitive description of the ordered test.
Cxbladder Monitor is designed for surveillance in people with a history of urothelial carcinoma. It is optimized to identify patients with a low probability of recurrence while flagging those who need clinician-directed investigation. Current reporting uses a cutoff around 3.5, with lower scores categorized as low probability of recurrent urothelial carcinoma.
The numbers from these versions are not interchangeable. A Triage Plus score of 0.20 and a Monitor score of 3.0 live on different scales and answer different questions.
This version dependence is especially important when reading information published several years apart. Cxbladder has evolved, and older studies may describe Detect or the original Triage algorithm while newer U.S. materials emphasize Triage Plus. The gene-expression backbone remains related, but added DNA markers, reporting bands, and decision thresholds can change. A patient should identify the exact assay name and report date before applying any published performance figure or cutoff.
Who May Be Tested and Why
Cxbladder is most relevant in two settings: evaluating hematuria and following a patient with a history of non-muscle-invasive urothelial cancer.
Hematuria can be visible to the eye or detected only on microscopy. Many causes are benign, including urinary infection, stones, prostate bleeding, exercise, menstruation, and kidney disease, but urothelial cancer must be considered in the right risk group. Traditional evaluation can involve cystoscopy and imaging of the upper urinary tract.
The 2025 AUA/SUFU microhematuria guideline incorporated updated evidence on urine-based tumor markers. In appropriately counseled intermediate-risk patients who wish to avoid cystoscopy and accept the associated uncertainty, a validated urine-based tumor marker or cytology can be used to help decide whether cystoscopy is needed. This is not the same as recommending a marker for every person with hematuria. High-risk patients generally still require direct evaluation.
The STRATA randomized trial is especially relevant to Cxbladder Triage. In lower-risk participants, providing the Triage result reduced cystoscopy use by 59%. The assay showed 90% sensitivity and 99% negative predictive value in the trial population, but specificity was 56%. These numbers illustrate why the test is more useful for ruling out disease in selected lower-risk patients than for proving that cancer is present.
For recurrence surveillance, Cxbladder Monitor may be considered as part of a urologist-directed plan. It does not automatically replace cystoscopy in every patient. A person with previous high-grade T1 cancer or carcinoma in situ has a different recurrence and progression risk from someone with a single low-grade Ta tumor, and surveillance intensity should reflect that difference.
A urine cytology test may still be valuable, especially when high-grade disease or carcinoma in situ is a concern.
Urine Sample Collection and Processing
Cxbladder uses a midstream voided urine sample, so the collection itself is noninvasive. Current manufacturer information describes using about 5 mL of urine for laboratory molecular analysis after the sample has been collected in the supplied system.
A typical collection involves these steps:
- Begin urinating into the toilet.
- Collect the midstream portion in the supplied container as instructed.
- Secure the specimen and mix it with any stabilizing solution provided by the test kit.
- Label the sample accurately.
- Send it to the designated laboratory according to shipping instructions.
The stabilizing system is important because RNA degrades easily. The laboratory needs an adequate cellular and molecular sample to produce a valid result. A report may occasionally be nonreportable if sample quality or quantity is insufficient.
There is generally no fasting requirement. Patients should still tell the clinician about active urinary infection, recent instrumentation, gross hematuria, and recent bladder treatment because these details influence the clinical interpretation even if the assay includes mechanisms intended to account for inflammation.
Unlike a 24-hour urine test, Cxbladder does not require collecting every urination for a full day. It is also not a home-read rapid test. The molecular extraction, amplification, and algorithmic calculation are performed in a laboratory.
Because test versions and ordering pathways differ across countries, the specimen instructions supplied with the current kit should always take priority over generic collection advice.
Understanding Cxbladder Risk Scores
A Cxbladder score is a probability classification, not a tumor stage and not a percentage of the bladder occupied by cancer. Interpretation starts by identifying the assay name on the report.
For Cxbladder Triage Plus, current reporting uses a 0.0 to 1.0 scale. Manufacturer reporting describes scores below 0.15 as low probability. Scores from 0.15 to below 0.54 are intermediate probability, and scores 0.54 or higher are high probability. In its analytical-development data, the low cutoff was associated with a predicted negative predictive value of about 99.4%, while the higher threshold improved positive predictive value. External prospective validation is important because predictive values change with cancer prevalence.
For Cxbladder Monitor, current information uses 3.5 as the main threshold. A score below 3.5 indicates a low probability of recurrent urothelial carcinoma, while a score at or above 3.5 signals that clinician-directed investigation is warranted.
| Result | What it means | What it does not mean |
|---|---|---|
| Low probability | The molecular pattern makes urothelial cancer less likely in the tested population | It is not a guarantee that cancer is absent |
| Intermediate probability | The result does not confidently rule out disease | It is not a diagnosis of cancer |
| High probability or positive-range score | The result raises concern and supports further urologic evaluation | It does not establish tumor grade, stage, or location |
| Nonreportable | The laboratory could not produce a valid classification | It should not be interpreted as negative |
Negative predictive value is particularly important with Cxbladder. A 99% NPV means that among people in a similar tested population who receive a negative result, about 99% did not have the target cancer outcome. It does not mean an individual’s cancer risk is exactly 1% regardless of age, smoking, hematuria severity, or prior history.
The same principle applies to positive predictive value. A high-probability score is more convincing when the tested group already has a meaningful chance of urothelial cancer. In very low-risk people, even a highly specific molecular result can generate avoidable follow-up. That is why guideline-supported use is tied to defined clinical settings rather than broad population screening. The test is designed to modify a pre-existing risk estimate, not to create one from zero clinical context.
Accuracy, Limitations, and Comparison With Other Tests
Cxbladder has stronger contemporary clinical evidence than many older urinary protein markers, but it still has limitations. The largest practical limitation is that performance depends on the population and test version. Triage, Triage Plus, Detect, and Monitor have different algorithms, cutoffs, and intended uses.
The 2024 STRATA randomized trial found Cxbladder Triage sensitivity of 90%, specificity of 56%, and NPV of 99% for urothelial carcinoma in its study cohort. A 2025 analytical validation of Triage Plus projected sensitivity of 93.6% and specificity of 90.8% at the 0.15 threshold in a development dataset. A later prospective DRIVE validation reported sensitivity around 94%, specificity around 77%, and NPV around 99% for Triage Plus. These results are encouraging but should not be blended into one universal “Cxbladder accuracy” figure.
Compared with NMP22 or BTA protein assays, Cxbladder uses multiple molecular signals and is designed to account for some inflammatory effects. Compared with cystoscopy, however, it cannot directly visualize a lesion. Compared with pathology, it cannot determine grade, invasion, variant histology, or carcinoma in situ with certainty.
False-negative results remain possible. Missing a high-grade tumor has much greater clinical consequence than delaying cystoscopy in a very low-risk patient, so risk selection matters. False-positive or intermediate results can also lead to cystoscopy that ultimately shows no cancer.
Costs, insurance coverage, test access, sample logistics, and regional availability also influence whether the test is practical. These issues can change over time and should be checked at the point of care.
A nonreportable result deserves separate attention. It can occur when the sample does not meet laboratory quality requirements, and it should not be treated as a low-risk score. Depending on the reason, the clinician may request another specimen or proceed using the other clinical information already available. Repeating a molecular urine test is most useful when a corrected collection can realistically produce a valid answer and when that answer could still change management.
A molecular score can also be discordant with cystoscopy or cytology because the methods observe different aspects of disease. Cxbladder detects a molecular pattern in shed urinary material, cystoscopy visualizes the bladder surface, and cytology evaluates cell morphology. A low molecular score does not make a clearly suspicious lesion disappear, while a high score does not create a visible tumor when cystoscopy is normal. Discordant findings should trigger risk-based clinical judgment rather than automatic repetition of the same test.
What Happens After the Result
The next step should be based on the combination of Cxbladder result and clinical risk. A low result is most useful when the patient was already in a setting where avoiding immediate cystoscopy is a reasonable option. It is much less appropriate as reassurance in someone with visible hematuria, heavy smoking exposure, abnormal imaging, or other high-risk features.
For an intermediate or high-probability result during hematuria evaluation, the usual next step is urologic assessment. Cystoscopy can inspect the bladder, while upper-tract imaging evaluates the kidneys and ureters. If a lesion is identified, transurethral resection or biopsy provides the tissue needed for diagnosis.
For a Monitor result at or above the assay threshold, the report is best read as a signal to follow the surveillance protocol, not proof that the tumor has returned. A low Monitor result may support a less invasive strategy in selected patients when a urologist is using a validated marker-guided pathway.
Results should also be reconciled with symptoms. Persistent visible blood in urine, unexplained irritative urinary symptoms, or abnormal cytology should not be dismissed because a molecular test is low risk. Conversely, a high molecular score with a normal cystoscopy may prompt the clinician to consider whether repeat evaluation, cytology, enhanced cystoscopy, or upper-tract assessment is appropriate based on the overall picture.
The best use of Cxbladder is decision support: it can sharpen risk estimates and sometimes reduce unnecessary invasive testing, but it remains part of a broader diagnostic strategy rather than a stand-alone bladder-cancer answer.
References
- Updates to Microhematuria: AUA/SUFU Guideline (2025) 2025 (Guideline)
- A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial 2024 (RCT)
- Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma 2025
- Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification 2023
- Urine biomarkers in bladder cancer – current status and future perspectives 2023 (Review)
- Understanding the Cxbladder Test Report 2026
Disclaimer
This article is for general educational purposes and does not replace individualized urologic advice. Cxbladder versions, score cutoffs, availability, and coverage can change, so interpret the exact report using the current laboratory guidance and your clinician’s risk assessment. Seek prompt medical evaluation for visible blood in urine, especially when persistent or accompanied by clots, pain, fever, or difficulty urinating.
